UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM | ||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 13, 2024
(Exact name of Registrant, as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||||||||
Mailing address:
(Address of principal executive
offices)
Registrant's telephone number, including area code: (858 ) 412-8151
Former name or address, if changed since last report: Not Applicable.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 13, 2024, Cue Health Inc. ("Cue Health" or the "Company"), issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information contained this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | ||||
| Press Release issued by Cue Health dated March 13, 2024. | |||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document). | ||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cue Health Inc. | ||||||||
| Date: March 13, 2024 | By: | /s/ Aasim Javed | ||||||
| Name: | Aasim Javed | |||||||
| Title: | Chief Financial Officer | |||||||
3
Cue Health Reports Fourth Quarter 2023 Financial Results
____________________
SAN DIEGO, CA – March 13, 2024 – Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023.
Recent Highlights
•Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million
•Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission
•Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission
•In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24
•Executed cost reduction plans, resulting in cash savings of approximately $200 million on an annualized basis, while prioritizing near-term revenue generating opportunities
•Reported cash and cash equivalents of $80.9 million as of December 31, 2023
“We made progress executing on our strategic priorities in 2023. We obtained two FDA authorizations including a de novo approval for our COVID-19 Molecular Test and an EUA for our Mpox Molecular Test, and made two de novo submissions for our RSV and Flu standalone molecular tests. We also drove significant development progress on our all-in-one Flu + COVID-19 + RSV test, our Herpes + Mpox multiplex test, and we expanded our Integrated Care Platform with a new suite of at-home diagnostics tests and treatments, all while streamlining our cost structure,” said Ayub Khattak, Chairman and CEO of Cue. “We believe that these successes have positioned us well for 2024.”
Fourth Quarter 2023 Financial Results
Revenue was $18.8 million for the fourth quarter of 2023. Private sector revenue was $17.0 million or 91% of total revenue with strong ordering from existing customers. Public sector revenue was $1.8 million and disposable test cartridge revenue was $15.5 million.
GAAP product gross profit was a loss of $18.4 million in the fourth quarter of 2023. Adjusted product gross profit was a loss of $2.7 million after excluding one-time $15.7 million inventory charges.
GAAP operating costs and expenses in the fourth quarter of 2023 were $132.0 million, excluding cost of product revenue. GAAP operating costs and expenses includes $83.6 million of impairment of long-lived assets. Adjusted operating costs and expenses were $48.3 million in the fourth quarter of 2023, a 49% decrease from $94.6 million in the fourth quarter of 2022.
GAAP net loss in the fourth quarter of 2023 was $148.4 million and earnings per diluted share was a loss of $0.96. Cue's adjusted net loss, which excludes the one-time inventory and impairment charges, was $49.1 million and adjusted earnings per diluted share was a loss of $0.32. Adjusted EBITDA was a loss of $24.4 million.
Full-Year 2023 Financial Results
Revenue was $70.9 million for the full year of 2023. Private sector revenue was $63.0 million, or 89% of total revenue. Public sector revenue was 11% of total revenue or $7.9 million. Disposable test cartridge revenue was $58.5 million for the full year 2023.
GAAP product gross profit was a loss of $62.9 million for the full year 2023. Adjusted product gross profit was a loss of $35.2 million after excluding a $12.0 million disputed vendor payment and the one-time inventory charges of $15.7 million.
GAAP operating costs and expenses for the full year 2023 were $338.7 million, excluding cost of product revenue. GAAP operating costs and expenses includes $83.6 million of impairment of long-lived assets and $14.5 million of restructuring expense. Adjusted operating costs and expenses for the full year 2023 were $240.6 million.
GAAP net loss for the full year 2023 was $373.5 million and earnings per diluted share was a loss of $2.44. Cue's Adjusted net loss was $267.2 million and adjusted earnings per diluted share was a loss of $1.75. Adjusted EBITDA was a loss of $163.8 million.
Cash and cash equivalents were $80.9 million as of December 31, 2023 and Cue continues to operate with no debt obligations.
Guidance
Cue expects first quarter 2024 revenues in the range of $9 million to $11 million.
Webcast and Conference Call Information
Cue will host a conference call to discuss the fourth quarter and full year 2023 financial results, after market close on Wednesday, March 13, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.
The live webinar may be accessed by visiting the “Events” section of the Company’s website at investors.cuehealth.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.
About Cue
Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue’s platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive this FDA approval. Cue also received Emergency Use Authorization from the FDA for its molecular Mpox test at the point-of-care and, to expand its test menu, Cue has a number of other submissions under review by the FDA. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, including statements related to the submission of any FDA applications and expectations around receiving clearance and authorization and timing of such clearance, authorization and submissions, growth in our customer base, expectations regarding production capacity and product launches, potential technology enhancements, expectations related to availability of our programs and testing volumes, the ability to achieve growth in the future, and future results of operations and performance and our guidance, including first quarter 2024 guidance, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. The words, without limitation, “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “would,” “develop,” “pave,” “seek,” “offer,” “grow”, “expand”, “look forward”, “believe,” “design” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those related to expectations around FDA submissions, applications, authorizations and timing, the expected capabilities of the flu A/B standalone, flu A/B + COVID multiplex, RSV test, Strep Throat test, Mpox test and Chlamydia + Gonorrhea multiplex
test, the expansion of Cue Care, our ability to maintain customer growth rates, our ability to increase private sector revenue, our ability maintain or replace the revenue historically generated from our government contracts, our ability to effectively scale our manufacturing capacity to meet contractual obligations with our customers and market demand, our ability to realize operating expense annualized savings as a result of the previously announced cost reduction program, and the factors discussed in the "Risk Factors" section of Cue’s Annual Report on Form 10-K for the year ended December 31, 2023, to be filed with the SEC. Any forward-looking statements contained in this press release are based on the current expectations of Cue’s management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
The Cue Mpox (Monkeypox) Molecular Test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA. This product has been authorized only for the detection of nucleic acid from monkeypox virus, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of infection with the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Use of Non-GAAP Financial Measures
To supplement our financial information presented in accordance with GAAP, we consider certain financial measures that are not prepared in accordance with GAAP, including Adjusted Product Gross Profit (Loss) Margin, Adjusted Operating Expenses, Adjusted Net Loss, Adjusted Diluted EPS and Adjusted EBITDA (loss). We use these financial measures in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies and to communicate with our board of directors concerning our business and financial performance. We believe that these non-GAAP financial measures provide useful information to investors about our business and financial performance, enhance their overall understanding of our past performance and future prospects, and allow for greater transparency with respect to metrics used by our management in their financial and operational decision making. We are presenting these non-GAAP financial measures to assist investors in seeing our business and financial performance through the eyes of management, and because we believe that these non-GAAP financial measures provide an additional tool for investors to use in comparing results of operations of our business over multiple periods with other companies in our industry.
Adjusted EBITDA is defined as net loss before interest income, interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation, impairment of long-lived assets, restructuring expense, tax credits, disputed vendor payment, inventory charges, U.S. Department of Defense (the “DoD”) deferred revenue release.
Adjusted product gross profit (loss) is defined as product gross profit (loss), before DoD deferred revenue release, disputed vendor payment, inventory charges.
Adjusted operating costs and expenses is defined as operating costs and expenses before cost of product revenue, impairment of long-lived assets, restructuring expense.
Adjusted net loss is defined as Net loss, before impairment of long-lived assets, restructuring expense, tax credits, disputed vendor payment, inventory charges and tax effects.
Adjusted diluted EPS is defined as Diluted EPS before impairment of long-lived assets, restructuring expense, tax credits, disputed vendor payment, inventory charges and tax effects.
Our definitions may differ from the definitions used by other companies and therefore comparability may be limited. In addition, other companies may not publish these or similar metrics. Further, these metrics have certain limitations in that they do not include the impact of certain expenses that are reflected in our consolidated statements of operations. Thus, these non-GAAP metrics should be considered in addition to, not as substitutes for, or in isolation from, measures prepared in accordance with GAAP. For reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures see the financial tables below.
Press
Cue Health
press@cuehealth.com
Investors
ICR Westwicke
Caroline Corner
+1-415-202-5678
caroline.corner@westwicke.com
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share data)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
Product revenue | $ | 17,381 | $ | 145,701 | $ | 64,223 | $ | 474,166 | |||||||||||||||
Grant and other revenue | 1,417 | 1,076 | 6,713 | 9,310 | |||||||||||||||||||
Total revenue | 18,798 | 146,777 | 70,936 | 483,476 | |||||||||||||||||||
| Operating costs and expenses: | |||||||||||||||||||||||
Cost of product revenue | 35,742 | 90,783 | 127,091 | 329,973 | |||||||||||||||||||
Sales and marketing | 6,226 | 19,312 | 32,584 | 88,580 | |||||||||||||||||||
Research and development | 32,248 | 56,149 | 150,620 | 171,452 | |||||||||||||||||||
General and administrative | 9,866 | 19,157 | 57,355 | 97,103 | |||||||||||||||||||
| Impairment of long-lived assets | 83,639 | — | 83,639 | — | |||||||||||||||||||
Restructuring expense | (18) | — | 14,500 | 2,020 | |||||||||||||||||||
Total operating costs and expenses | 167,703 | 185,401 | 465,789 | 689,128 | |||||||||||||||||||
| Loss from operations | (148,905) | (38,624) | (394,853) | (205,652) | |||||||||||||||||||
| Interest income | 1,084 | 1,988 | 6,240 | 3,328 | |||||||||||||||||||
Interest expense | (344) | (232) | (1,159) | (645) | |||||||||||||||||||
Tax credits | — | — | 20,939 | — | |||||||||||||||||||
Other income (expense), net | (207) | 46 | 162 | (835) | |||||||||||||||||||
| Net loss before income taxes | (148,372) | (36,821) | (368,671) | (203,804) | |||||||||||||||||||
| Income tax expense (benefit) | 60 | (5,315) | 4,793 | (9,748) | |||||||||||||||||||
| Net loss | $ | (148,432) | $ | (31,506) | $ | (373,464) | $ | (194,056) | |||||||||||||||
| Net loss per share – basic & diluted | $ | (0.96) | $ | (0.21) | $ | (2.44) | $ | (1.31) | |||||||||||||||
| Weighted-average number of shares used in computation of net loss per share – basic & diluted | 154,807,021 | 149,711,419 | 152,877,306 | 148,024,749 | |||||||||||||||||||
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts and share data)
| December 31, 2023 | December 31, 2022 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
Cash and cash equivalents | $ | 80,889 | $ | 241,530 | |||||||
Restricted cash | 800 | 800 | |||||||||
Accounts receivable, net | 1,352 | 18,751 | |||||||||
Inventories, net - current | 14,039 | 82,210 | |||||||||
Prepaid expenses | 8,479 | 15,728 | |||||||||
Other current assets | 4,803 | 12,134 | |||||||||
Total current assets | 110,362 | 371,153 | |||||||||
| Non-current inventories, net | 56,273 | 25,436 | |||||||||
| Property and equipment, net | 72,096 | 189,275 | |||||||||
| Operating lease right-of-use assets | 78,519 | 85,321 | |||||||||
| Intangible assets, net | 19,644 | 16,867 | |||||||||
| Other non-current assets | 2,893 | 6,528 | |||||||||
| Total assets | $ | 339,787 | $ | 694,580 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
Accounts payable | $ | 7,705 | $ | 7,150 | |||||||
Accrued liabilities and other current liabilities | 29,300 | 52,378 | |||||||||
Deferred revenue, current | 162 | 1,566 | |||||||||
Operating lease liabilities, current | 5,142 | 7,739 | |||||||||
Finance lease liabilities, current | 1,157 | 2,362 | |||||||||
Total current liabilities | 43,466 | 71,195 | |||||||||
| Operating leases liabilities, net of current portion | 41,640 | 44,045 | |||||||||
| Finance lease liabilities, net of current portion | — | 849 | |||||||||
| Other non-current liabilities | 4,429 | 1,997 | |||||||||
| Total liabilities | 89,535 | 118,086 | |||||||||
| Stockholders’ Equity | |||||||||||
| Common stock | 2 | 1 | |||||||||
| Additional paid-in-capital | 841,788 | 794,567 | |||||||||
| Accumulated deficit | (591,538) | (218,074) | |||||||||
| Total stockholders’ equity | 250,252 | 576,494 | |||||||||
| Total liabilities and stockholders’ equity | $ | 339,787 | $ | 694,580 | |||||||
Non-GAAP Measures
(In thousands, except share data)
The following table presents the reconciliation of Net loss to Adjusted EBITDA, for the periods presented:
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net loss | $ | (148,432) | $ | (31,506) | $ | (373,464) | $ | (194,056) | |||||||||||||||
| Interest income | (1,084) | (1,988) | (6,240) | (3,328) | |||||||||||||||||||
| Interest expense | 344 | 232 | 1,159 | 645 | |||||||||||||||||||
| Income tax expense (benefit) | 60 | (5,315) | 4,793 | (9,748) | |||||||||||||||||||
| Depreciation and amortization | 15,219 | 14,337 | 56,278 | 48,972 | |||||||||||||||||||
| Stock-based compensation | 10,138 | 15,776 | 48,735 | 64,291 | |||||||||||||||||||
| Impairment of long-lived assets | 83,639 | — | 83,639 | — | |||||||||||||||||||
| Restructuring expense | (18) | — | 14,500 | 2,020 | |||||||||||||||||||
| Tax credits | — | — | (20,939) | — | |||||||||||||||||||
| Disputed vendor payment | — | — | 12,000 | — | |||||||||||||||||||
| Inventory charges | 15,705 | 47,352 | 15,705 | 92,806 | |||||||||||||||||||
| DoD deferred revenue release | — | (92,448) | — | (92,448) | |||||||||||||||||||
| Adjusted EBITDA | $ | (24,429) | $ | (53,560) | $ | (163,834) | $ | (90,846) | |||||||||||||||
The following table presents the reconciliation of Product gross profit (loss) margin to Adjusted product gross profit (loss) margin, for the periods presented:
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Product revenue | $ | 17,381 | $ | 145,701 | $ | 64,223 | $ | 474,166 | |||||||||||||||
Cost of product revenue | 35,742 | 90,783 | 127,091 | 329,973 | |||||||||||||||||||
Product gross profit (loss) | $ | (18,361) | $ | 54,918 | $ | (62,868) | $ | 144,193 | |||||||||||||||
Product gross profit (loss) margin | (106) | % | 38 | % | (98) | % | 30 | % | |||||||||||||||
| DoD deferred revenue release | — | (92,448) | — | (92,448) | |||||||||||||||||||
| Adjusted product revenue | 17,381 | 53,253 | 64,223 | 381,718 | |||||||||||||||||||
Disputed vendor payment | — | — | 12,000 | — | |||||||||||||||||||
| Inventory charges | 15,705 | 47,352 | 15,705 | 92,806 | |||||||||||||||||||
| Adjusted product gross profit (loss) | $ | (2,656) | $ | 9,822 | $ | (35,163) | $ | 144,551 | |||||||||||||||
| Adjusted product gross profit (loss) margin | (15) | % | 18 | % | (55) | % | 38 | % | |||||||||||||||
The following table presents the reconciliation of Operating costs and expenses to Adjusted operating costs and expenses, for the periods presented:
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Operating costs and expenses | $ | 167,703 | $ | 185,401 | $ | 465,789 | $ | 689,128 | |||||||||||||||
Cost of product revenue | 35,742 | 90,783 | 127,091 | 329,973 | |||||||||||||||||||
| Operating costs and expenses excluding cost of product revenue | 131,961 | 94,618 | 338,698 | 359,155 | |||||||||||||||||||
Impairment of long-lived assets | 83,639 | — | 83,639 | — | |||||||||||||||||||
| Restructuring expense | (18) | — | 14,500 | 2,020 | |||||||||||||||||||
| Adjusted operating costs and expenses | $ | 48,340 | $ | 94,618 | $ | 240,559 | $ | 357,135 | |||||||||||||||
The following table presents the reconciliation of Net loss / diluted EPS to Adjusted net loss / diluted EPS, for the periods presented:
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2023 | 2023 | ||||||||||||||||||||||
| Dollar Amount | Per Diluted Share | Dollar Amount | Per Diluted Share | ||||||||||||||||||||
| Net loss / diluted EPS | $ | (148,432) | $ | (0.96) | $ | (373,464) | $ | (2.44) | |||||||||||||||
| Impairment of long-lived assets | 83,639 | 0.54 | 83,639 | 0.55 | |||||||||||||||||||
Restructuring expense | (18) | — | 14,500 | 0.09 | |||||||||||||||||||
Tax credits | — | — | (20,939) | (0.14) | |||||||||||||||||||
Disputed vendor payment | — | — | 12,000 | 0.08 | |||||||||||||||||||
| Inventory charges | 15,705 | 0.10 | 15,705 | 0.10 | |||||||||||||||||||
Tax effects | 40 | — | 1,364 | 0.01 | |||||||||||||||||||
| Adjusted net loss / diluted EPS | $ | (49,066) | $ | (0.32) | $ | (267,195) | $ | (1.75) | |||||||||||||||